Insilico Medicine Stocks Turn Profitable in H1 2026 with USD 33.5-39.5M Net Profit

Insilico Medicine (03696) issued a profit alert for the first half of 2026 ended June 30, reporting net profit of USD 33.5 million to USD 39.5 million, compared to a net loss of USD 19.2 million in H1 2025. The Hong Kong-listed biotech company attributed the turnaround to increased revenue from licensing, co-development, and research collaboration agreements, alongside systematic improvements in operational efficiency. Revenue for H1 2026 reached USD 103 million to USD 107 million, representing a year-over-year increase of 2.73 to 2.87 times, while adjusted non-IFRS net profit totaled USD 45.5 million to USD 51.5 million versus a net loss of USD 15.4 million in the prior-year period.

Insilico Medicine Reports H1 2026 Financial Results

The company's H1 2026 net profit of USD 33.5 million to USD 39.5 million marked a reversal from the USD 19.2 million net loss recorded in H1 2025. Revenue for the six-month period ended June 30 stood at USD 103 million to USD 107 million, up 2.73 to 2.87 times year-over-year. Adjusted non-IFRS net profit for H1 2026 reached USD 45.5 million to USD 51.5 million, compared to a net loss of USD 15.4 million in the same period of the previous year.

Board Attributes Growth to Licensing Revenue and Operational Efficiency

The board of directors stated that the increases in H1 2026 revenue, net profit, and adjusted non-IFRS net profit were primarily due to the group's continued revenue growth, including substantially higher income from licensing, co-development, and research collaboration agreements in H1 2026 compared to H1 2025. The board also cited systematic improvements in operational efficiency as a contributing factor to the financial performance.

FAQ

What was Insilico Medicine's net profit in H1 2026?
Insilico Medicine reported net profit of USD 33.5 million to USD 39.5 million for the first half of 2026 ended June 30, compared to a net loss of USD 19.2 million in H1 2025.

How much did Insilico Medicine's revenue grow in H1 2026?
Revenue for H1 2026 reached USD 103 million to USD 107 million, representing a year-over-year increase of 2.73 to 2.87 times compared to H1 2025.

Why did Insilico Medicine's financial performance improve in H1 2026?
The board attributed the improvement to increased revenue from licensing, co-development, and research collaboration agreements, along with systematic enhancements in operational efficiency.